Tura S, Mandelli F, Mazza P, Cimino G, Anselmo A P, Amadori S
Chemioterapia. 1984 Apr;3(2):79-82.
Eighteen patients with advanced refractory lymphomas were treated with 2-methyl-hydroxyellipticinium (ellipticinium); there were 14 non-Hodgkin's (NHL) and 4 Hodgkin's lymphomas (HL). Ellipticinium was administered at the dose of 100 mg/m2 daily for 3 days i.v. with courses repeated at 3 week intervals. Preliminary results indicate some antitumor activity of the drug against NHL with minimal toxicity. Of the 16 evaluable patients 1 partial remission and 7 minor responses were noted among the NHL (65%). Myelosuppression was minimal and clinical toxicity was mild. Further evaluation of this drug in untreated patients appears to be warranted.
18例晚期难治性淋巴瘤患者接受了2-甲基羟基玫瑰树碱（玫瑰树碱）治疗；其中14例为非霍奇金淋巴瘤（NHL），4例为霍奇金淋巴瘤（HL）。玫瑰树碱静脉注射给药，剂量为100mg/m²，每日1次，共3天，疗程每3周重复一次。初步结果表明该药物对NHL有一定抗肿瘤活性，毒性极小。在16例可评估的患者中，NHL患者中有1例部分缓解，7例轻微缓解（65%）。骨髓抑制轻微，临床毒性较轻。对该药物在未治疗患者中的进一步评估似乎是必要的。
